Orforglipron
0.5mg x 25 tablets
Orforglipron is an orally bioavailable, non-peptide small-molecule GLP-1 receptor agonist developed by Eli Lilly (LY3502970). Unlike peptide-based GLP-1 agents, it is a synthetic small molecule that activates the GLP-1 receptor without an injectable format or an absorption enhancer. Supplied strictly for in-vitro research and laboratory use only.
Select Option
10% OFF · ends July 31Mechanism of Action
Orforglipron is a once-daily, non-peptide small-molecule agonist of the glucagon-like peptide-1 (GLP-1) receptor. It activates the receptor through a small-molecule binding mode distinct from peptide agonists, and unlike oral semaglutide it does not require a permeation/absorption enhancer or fasting and water restrictions. It is a GLP-1-only agent, distinct from tirzepatide, which is an injectable dual GIP/GLP-1 peptide.
Properties
Storage
Store at room temperature in a cool, dry place. Protect from moisture.
Research Applications
References & Citations
(3)Structural basis for GLP-1 receptor activation by LY3502970, an orally active nonpeptide agonist
Kawai T, Sun B, Yoshino H, et al.
Effect of food consumption on the pharmacokinetics, safety, and tolerability of once-daily orally administered orforglipron (LY3502970), a non-peptide GLP-1 receptor agonist
Ma X, Liu R, Pratt EJ, et al.
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes (ACHIEVE-1)
Rosenstock J, Hsia S, Nevarez Ruiz L, et al.
Research Use Only
This product is intended strictly for in-vitro research, educational, and laboratory use. Not for human consumption. The information provided is based on published research and does not constitute medical advice.